top of page


SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented

Updated: Dec 7, 2022

Every year since 1977, the San Antonio Breast Cancer Symposium (SABCS), which is now organized in collaboration with the Cancer Therapy and Research Center (CTRC) at UT Health Science Center San Antonio and the American Association for Cancer Research (AACR), is celebrated in San Antonio (Texas, USA)

Although this year’s event, as many others, will have to be virtual, it will still aim to provide state-of-the-art information on biology, etiology, prevention, diagnosis and treatment of breast cancer to an international audience of academic and private researchers and physicians from over 90 countries.

The Symposium will take place between the 8th and the 11th of December. This year, MEDSIR will communicate novel results from two MEDSIR-sponsored studies: the PARSIFAL and the BIOPER clinical trials.

The PARSIFAL study was an international, randomized, open-label phase II trial that aimed at exploring the optimal endocrine agent, fulvestrant or letrozole, to combine with palbociclib as initial therapy for patients with endocrine-sensitive, estrogen receptor positive (ER[+]) and human epidermal growth factor receptor 2 negative (HER2[-]) metastatic breast cancer (MBC). At SABCS 2020, Dr José Manuel Pérez-García from the International Breast Cancer Center (IBCC), Quirón Group (Barcelona, Spain) will present findings from a comprehensive analysis of the safety and tolerability profile of both combinative regimens, with a particular emphasis on venous thromboembolism. The results from the PARSIFAL study might help physicians decide what is the best drug combination to use in the treatment of this subtype of patients with advanced breast cancer.

· Abstract title: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)

· Abstract number: PS10-17

The BIOPER was a multicenter, open-label, non-controlled phase II trial with two co-primary objectives: i) To assess the clinical benefit of palbociclib plus endocrine therapy in metastatic breast cancer patients who had previously received hormone therapy combined with palbociclib and achieved clinical benefit followed by disease progression; ii) To investigate a molecular profile able to identify patients that could benefit from maintaining palbociclib treatment after progression on a prior palbociclib-containing regimen. During the poster session at SABCS, Dr Antonio Llombart-Cussac, Head of Medical Oncology Service at Hospital Arnau de Vilanova (Valencia, Spain) will report findings from this relevant study. The results from the BIOPER study will help understand what are the best treatment options for breast cancer patients that stop responding to palbociclib therapy, and contribute to personalize patients’ treatment according to their specific characteristics.

· Abstract title: A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)

· Abstract number: PS10-27

Both communications will be displayed during the SABCS’ Poster Session #10 on Wednesday 9th of December, at 8:00AM GMT-7.

If you would like to know more about how MEDSIR helped oncology investigators turn their ideas into these fully-funded independent clinical trials, or about any other MEDSIR-sponsored studies, do not hesitate to get in touch with us.



bottom of page